Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCRIT: Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer
NCT07686640Phase 3Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Aug 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 3 trial of iparomlimab, tuvonralimab in rectal adenocarcinoma, sponsored by Shandong Cancer Hospital. Started Aug 2026; status: recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT07686640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07686640.